AstraZeneca PLC has its sights set on speeding up the US Food and Drug Administration review of an upcoming new drug filing. The company revealed on 22 August that it paid $95m to buy a priority review voucher from Swedish Orphan Biovitrum AB.
An FDA priority review cuts the timeline for reviewing a new drug from 10 months to six months, excluding the...






